https://www.selleckchem.com/pr....oducts/acalabrutinib
This study shows that SCT may represent an alternative therapeutic option for transfusion-dependent younger patients.Immunoglobulin D (IgD) multiple myeloma (MM) is a rare subtype of MM that carries a worse prognosis than non-IgD subtypes. Compared with non-IgD subtypes, IgD MM is associated with a shorter survival time. The application of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed or refractory multiple myeloma (R/R MM) has increasing evidence as an efficacious treatment. This study was designed to
Like
Comment
Share
